Enzastaurin
Phase 3Small molecule
Eli LillyEnzastaurin was being developed to treat certain cancers, particularly lymphomas and solid tumors, by blocking proteins that help cancer cells grow and survive.[1] Enzastaurin is currently being investigated across 27 indications[3], with its most advanced program in Phase 3.[1]
Enzastaurin is one of 651 small molecule programs targeting Glioma. It is currently in Phase 3.
27
Indications
49
Total Trials
0
Active Trials
650
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 27 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Enzastaurin
Eli LillyPhase 3
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Megace
Bristol-Myers SquibbPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Dextromethorphan Hydrobromide
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphoma5 trials
Lung Cancer5 trials
Breast Cancer4 trials
Non-Small Cell Lung Cancer4 trials
25 more indications
Prostate Cancer3 trials
Glioma2 trials
Interaction1 trial
Malignant Glioma1 trial
Glioblastoma Multiforme1 trial
Pancreatic Cancer1 trial
Colorectal Cancer1 trial
Ovarian Cancer1 trial
Metastatic Cancer1 trial
Recurrent Ovarian Epithelial Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Biomarker1 trial
Primary Peritoneal Cancer1 trial
Metastatic Colon Cancer1 trial
Ehlers-Danlos syndrome1 trial
Macroglobulinemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enzastaurin. EMBL-EBI & Wellcome Sanger Institute.
- [4]